Avenue Therapeutics, Inc. (ATXI)

$0.288

-0.01 (-2.67%)
Rating:
Recommendation:
Buy
Symbol ATXI
Price $0.288
Beta 0.948
Volume Avg. 0.27M
Market Cap 6.375M
Shares () -
52 Week Range 0.2-1.85
1y Target Est -
DCF Unlevered ATXI DCF ->
DCF Levered ATXI LDCF ->
ROE -813.75% Strong Sell
ROA -529.60% Strong Sell
Operating Margin -
Debt / Equity 68.77% Buy
P/E -
P/B 5.21 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ATXI news


Dr. Lucy Lu
Healthcare
Biotechnology
NASDAQ Capital Market

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.